Company Description

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.

The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.

BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd.

Country	Israel
Founded	2003
IPO Date	Jul 25, 2011
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Philip Serlin

Contact Details

Address: Modi’in Technology Park, 2 HaMa’ayan Street Hevel Modi'in, 7177871 Israel
Phone	972 8 642 9100
Website	biolinerx.com

Stock Details

Ticker Symbol	BLRX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001498403
CUSIP Number	09071M304
ISIN Number	US09071M3043
SIC Code	2834

Key Executives

Name	Position
Dr. Ella Sorani Ph.D.	Chief Development Officer
John Lacey	Head of Corporate Communications and Investor Relations
Raziel Fried	Treasurer and Budgetary Control Director

Latest SEC Filings

Date	Type	Title
Nov 24, 2025	6-K	Report of foreign issuer
Nov 17, 2025	6-K	Report of foreign issuer
Sep 29, 2025	6-K	Report of foreign issuer
Aug 14, 2025	SCHEDULE 13G	Filing
Aug 14, 2025	6-K	Report of foreign issuer
Jul 25, 2025	424B5	Filing
Jun 30, 2025	6-K	Report of foreign issuer
May 30, 2025	6-K	Report of foreign issuer
May 27, 2025	6-K	Report of foreign issuer
May 23, 2025	6-K	Report of foreign issuer

View All SEC Filings